Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience.
BRAF
molecular target
optic pathway gliomas
optic pathway surgery
pediatric neuro-oncology
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
03
2022
accepted:
31
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Optic pathway gliomas (OPGs) are rare neoplasms in children with an unpredictable clinical course. Approximately 15% of OPGs occur in patients affected by neurofibromatosis type 1 (NF1): the clinical course of these cases is more indolently than sporadic ones, and NF1 patients less frequently require treatment including surgery. Instead, over 90% of sporadic OPGs require one or more therapeutic approaches. The management of OPG is controversial. They are also characterized by a high risk of morbidity including hypothalamic damage, endocrine deficits, visual deficit and/or neurological impairment. In this paper, we evaluated visual and endocrinological outcomes of a population of OPG followed at our center from 2013 to 2021, with a particular emphasis on the role of surgery. Twenty-six patients were included in this study (mean age of 40.7 months). Tumor location on imaging was described by the Dodge classification. Five cases had NF 1. Thirteen cases received biopsy and 13 were partially resected. Histopathology revealed 19 cases of pilocytic astrocytomas, 2 pilomyxoid astrocytoma and 5 ganglioglioma. All the patients required a post-surgical adjuvant treatment according to current indications for low-grade gliomas. Molecular studies (BRAF status and mTOR/pmTOR pathway) have been performed in 24/26 patients, following for the use of target therapy in 11 of these patients. In our study we found that patients underwent biopsy have a better visual and endocrinological outcomes rather than patients with a tumor debulking. The five-year overall survival rate is 98% with a mean follow-up of 60 months. Many children with OPGs survive with a residual tumor. They suffer from chronic diseases such as endocrine dysfunction, visual disturbance, motor deficits and poor quality of life. All patients need comprehensive diagnostic work-up including neuroimaging, clinical evaluations and neuropathology approach; at the same time, they need therapeutic decisions and concepts for the choice of timing and type of neurosurgical intervention, chemotherapy and target therapy as well as surveillance and rehabilitation to maximize survival and overall functional outcomes. Our study showed that minimal invasive surgery with the purpose of molecular characterization of the tumor is desirable to reduce morbidity correlate to surgery.
Sections du résumé
Background
UNASSIGNED
Optic pathway gliomas (OPGs) are rare neoplasms in children with an unpredictable clinical course. Approximately 15% of OPGs occur in patients affected by neurofibromatosis type 1 (NF1): the clinical course of these cases is more indolently than sporadic ones, and NF1 patients less frequently require treatment including surgery. Instead, over 90% of sporadic OPGs require one or more therapeutic approaches. The management of OPG is controversial. They are also characterized by a high risk of morbidity including hypothalamic damage, endocrine deficits, visual deficit and/or neurological impairment.
Materials and Methods
UNASSIGNED
In this paper, we evaluated visual and endocrinological outcomes of a population of OPG followed at our center from 2013 to 2021, with a particular emphasis on the role of surgery.
Results
UNASSIGNED
Twenty-six patients were included in this study (mean age of 40.7 months). Tumor location on imaging was described by the Dodge classification. Five cases had NF 1. Thirteen cases received biopsy and 13 were partially resected. Histopathology revealed 19 cases of pilocytic astrocytomas, 2 pilomyxoid astrocytoma and 5 ganglioglioma. All the patients required a post-surgical adjuvant treatment according to current indications for low-grade gliomas. Molecular studies (BRAF status and mTOR/pmTOR pathway) have been performed in 24/26 patients, following for the use of target therapy in 11 of these patients. In our study we found that patients underwent biopsy have a better visual and endocrinological outcomes rather than patients with a tumor debulking. The five-year overall survival rate is 98% with a mean follow-up of 60 months.
Conclusions
UNASSIGNED
Many children with OPGs survive with a residual tumor. They suffer from chronic diseases such as endocrine dysfunction, visual disturbance, motor deficits and poor quality of life. All patients need comprehensive diagnostic work-up including neuroimaging, clinical evaluations and neuropathology approach; at the same time, they need therapeutic decisions and concepts for the choice of timing and type of neurosurgical intervention, chemotherapy and target therapy as well as surveillance and rehabilitation to maximize survival and overall functional outcomes. Our study showed that minimal invasive surgery with the purpose of molecular characterization of the tumor is desirable to reduce morbidity correlate to surgery.
Identifiants
pubmed: 35784925
doi: 10.3389/fsurg.2022.890875
pmc: PMC9243477
doi:
Types de publication
Journal Article
Langues
eng
Pagination
890875Informations de copyright
Copyright © 2022 Del Baldo, Cacchione, Dell'anna, Merli, Colafati, Marrazzo, Rossi, Giovannoni, Barresi, Deodati, Valente, Ferretti, Capece, Mastronuzzi and Carai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuro Oncol. 2018 Jan 22;20(2):160-173
pubmed: 29016845
J Neurooncol. 2020 Sep;149(2):253-262
pubmed: 32780261
Nat Genet. 2013 Aug;45(8):927-32
pubmed: 23817572
Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):134-8
pubmed: 22583946
Eur J Paediatr Neurol. 2016 Mar;20(2):275-281
pubmed: 26774135
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
Clin Chem Lab Med. 2004;42(6):654-64
pubmed: 15259383
J Pediatr. 2015 Oct;167(4):851-856.e1
pubmed: 26233602
J Clin Oncol. 2012 Jul 20;30(21):2641-7
pubmed: 22665535
Neurosurg Focus. 2014;37(4):E11
pubmed: 25270130
Int J Cancer. 2020 Dec 15;:
pubmed: 33320972
Neurooncol Adv. 2019 Dec 20;2(Suppl 1):i98-i106
pubmed: 32642735
CNS Oncol. 2013 Mar;2(2):143-59
pubmed: 25057976
Acta Ophthalmol. 2018 Dec;96(8):e1004-e1009
pubmed: 30284379
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
Cancer. 2015 Dec 1;121(23):4190-6
pubmed: 26280460
Curr Opin Ophthalmol. 2006 Feb;17(1):7-11
pubmed: 16436918
Neurology. 2016 Jun 14;86(24):2264-70
pubmed: 27170570
Cancer Med. 2021 Jun;10(11):3556-3564
pubmed: 33939292
AMA Arch Neurol Psychiatry. 1958 Jun;79(6):607-21
pubmed: 13532071
Expert Rev Anticancer Ther. 2007 Nov;7(11):1591-610
pubmed: 18020927
Br J Radiol. 2008 Oct;81(970):761-6
pubmed: 18796556
Semin Pediatr Neurol. 2017 May;24(2):92-99
pubmed: 28941532
Pediatr Neurol. 2017 Oct;75:55-60
pubmed: 28847625
Br J Ophthalmol. 2018 Oct;102(10):1367-1371
pubmed: 29343527
Neurology. 2005 Oct 25;65(8):1335-6
pubmed: 16247081
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32294191
Am J Med Genet A. 2004 Jun 15;127A(3):224-9
pubmed: 15150770
J Neurooncol. 2012 May;107(3):591-7
pubmed: 22237948
J Neurosurg Pediatr. 2014 Jan;13(1):1-12
pubmed: 24138145
J Child Neurol. 2009 Nov;24(11):1397-408
pubmed: 19841428
J Neurosurg Pediatr. 2017 Dec;20(6):549-555
pubmed: 28984541
Clin Cancer Res. 2019 Dec 15;25(24):7303-7311
pubmed: 31811016
Eur J Cancer. 2006 Aug;42(12):1807-16
pubmed: 16809032
Childs Nerv Syst. 2021 Jun;37(6):1917-1929
pubmed: 33532921
J Pediatr Hematol Oncol. 2008 Mar;30(3):222-4
pubmed: 18376285
Neuro Oncol. 2021 Oct 1;23(10):1777-1788
pubmed: 33631016
Front Oncol. 2018 Nov 14;8:526
pubmed: 30488019
Neuro Oncol. 2020 Jun 9;22(6):773-784
pubmed: 32055852
Neuro Oncol. 2017 Jun 1;19(6):750-761
pubmed: 27683733
Arch Ophthalmol. 2001 Apr;119(4):516-29
pubmed: 11296017
Pediatr Blood Cancer. 2006 May 1;46(5):586-96
pubmed: 16411210
Adv Tech Stand Neurosurg. 2015;42:123-46
pubmed: 25411148
Childs Nerv Syst. 2020 Sep;36(9):1869-1886
pubmed: 32556546
Ann Neurol. 2007 Mar;61(3):189-98
pubmed: 17387725
J Clin Oncol. 2016 Oct 10;34(29):3537-3543
pubmed: 27573663